Fractyl Health, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Fractyl Health, Inc. operates as a pioneering metabolic therapeutics organization, dedicated to advancing novel solutions for the persistent challenges of type 2 diabetes and obesity. The company champions the Revita DMR System, an innovative outpatient procedural therapy designed to fundamentally address duodenal dysfunction. This condition, a pathological outcome stemming from diets rich in fats and sugars, is recognized as a key instigator of metabolic diseases in individuals. Through its distinct approach, Revita aims to durably modify the duodenum's role in metabolic regulation. Furthermore, Fractyl Health is developing Rejuva, an advanced gene therapy platform that utilizes a novel virus delivery mechanism targeting the pancreas. This platform is engineered to foster sustained remission in patients by enduringly modifying metabolic hormone function within pancreatic islet cells. The company, originally established as Fractyl Laboratories Inc. in 2010, rebranded to Fractyl Health, Inc. on June 9, 2021, and is based in Burlington, Massachusetts. Fractyl Health, Inc. recently completed an initial public offering in February 2024, listing on Nasdaq under the ticker symbol GUTS. The Revita DMR System, which has received FDA Breakthrough Device designation for type 2 diabetes and weight maintenance, is undergoing pivotal clinical studies, notably focusing on maintaining weight loss following GLP-1 therapy discontinuation. Early data from trials like REMAIN-1 indicates positive results for Revita in supporting weight management. The Rejuva gene therapy platform continues to progress, with candidates such as RJVA-001 having its first Clinical Trial Application module submitted in Europe, aiming for initial human studies and data reporting in 2026, while preclinical results for RJVA-002 demonstrate significant weight reduction in models of obesity. Fractyl Health's strategy emphasizes addressing the root physiological causes of these metabolic conditions, striving to shift treatment paradigms from chronic symptomatic management toward durable, disease-modifying interventions.
Company News
GUTS CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Fractyl (NASDAQ: GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Fractyl Health, Inc. to Contact Law Firm
GUTS DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Fractyl (GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026
Deadline Alert: Fractyl Health, Inc. Investors Have Until October 20, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds
Bronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 20, 2026 in Fractyl Health, Inc. Lawsuit - GUTS
Fractyl Health’s Revita Hits Key Weight-Maintenance Goal in REMAIN-1 Study
GUTS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Fractyl (GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026
Fractyl Health, Inc. (GUTS) Discusses Positive Top Line 6-Month Results From REMAIN-1 Study of Revita in Post GLP-1 Weight Maintenance Transcript
GUTS EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Fractyl Investors of Securities Class Action Lawsuit Deadline on October 20, 2026
Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
SueWallSt Reminds Fractyl Health, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 20, 2026 - GUTS
Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers - GUTS
GUTS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Fractyl (GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026
Portnoy Law Firm Announces Class Action on Behalf of Fractyl Health, Inc. Investors
Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GUTS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Fractyl Health, Inc. Securities Lawsuit - Contact Levi & Korsinsky
Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS